John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

The coexistence of two events does not prove their link! Volume 26, issue 2, Février 2019

  • [1] Cramer W., Guiot J., Faber M. Climate change and interconnected risks to sustainable development in the Mediterranean. Nature Climate Change. 2018;8:972-980.
  • [2] Payen J.L., Rongières M. Histoire des hépatites. De la jaunisse au virus. Rev Prat. 2002;52:2097-2100.
  • [3] Hippocrate de l’art médical. Paris: Librairie générale française; 1994. Hippocrate
  • [4] Payen J. Il était un foie. Les Ulis: EDP sciences; 2018.
  • [5] Dieulafoy G. Manuel de pathologie interne. Onzième éd. Paris : Masson et Cie ; 1898 : 663.
  • [6] Payen J.L. De la jaunisse à l’hépatite C : 5000 ans d’histoire. Paris: EDK; 2002.
  • [7] Herroelen L., de Keyser J., Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet. 1991;338:1174-1175.
  • [8] Sestili C, Grazina I, La Torre G. HBV vaccine and risk of developing multiple sclerosis: A systematic review and meta-analysis. Hum Vaccin Immunother 2018 ; 2018 : doi : 10.1080/21645515.2018.1528835.
  • [9] Reig M., Marino Z., Perello C. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
  • [10] Conti F., Buonfiglioli F., Scuteri A. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-733.
  • [11] ANRS. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734-740.
  • [12] Waziry R., Hajarizadeh B., Grebely J. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67:1204-1212.